| Manor Of Kenosha (the) | |
| 3100 Washington Rd, Kenosha, Wisconsin 53144 | |
| (262) 658-4622 | |
| Name | Manor Of Kenosha (the) |
|---|---|
| Location | 3100 Washington Rd, Kenosha, Wisconsin |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 153 |
| Occupancy Rate | 69.22% |
| Medicare ID (CCN) | 525179 |
| Legal Business Name | The Manor Of Kenosha Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1609823723 |
| Organization Name | HEARTLAND-WASHINGTON MANOR OF KENOSHA WI LLC |
| Doing Business As | HEARTLAND HEALTH CARE CENTER-WASHINGTON MANOR |
| Address | 3100 Washington Rd, Kenosha, WI 53144 |
| Phone Number | 262-658-4622 |
News Archive
The tongue helps people taste food, but structures on its surface also help them sense textures - something that's also very important when savoring a meal.
Precise Biometrics AB has successfully completed a rights issue with preferential rights, which has supplied the Company with SEK 54.0 million prior to issue costs. The rights issue was subscribed to 178% and is implemented to finance further expansion and increase market penetration in prioritized segments.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
With federal spending on Medicaid experiments soaring in recent years, a congressional watchdog said state and federal governments fail to adequately evaluate if the efforts improve care and save money.
The continuing efforts to make progress on the nation's health overhaul are reflected in today's headlines, which highlight both politics and policies.
› Verified 2 days ago
| NPI Number | 1730665159 |
| Organization Name | THE MANOR OF KENOSHA LLC |
| Address | 3100 Washington Rd, Kenosha, WI 53144 |
| Phone Number | 847-983-4860 |
News Archive
The tongue helps people taste food, but structures on its surface also help them sense textures - something that's also very important when savoring a meal.
Precise Biometrics AB has successfully completed a rights issue with preferential rights, which has supplied the Company with SEK 54.0 million prior to issue costs. The rights issue was subscribed to 178% and is implemented to finance further expansion and increase market penetration in prioritized segments.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
With federal spending on Medicaid experiments soaring in recent years, a congressional watchdog said state and federal governments fail to adequately evaluate if the efforts improve care and save money.
The continuing efforts to make progress on the nation's health overhaul are reflected in today's headlines, which highlight both politics and policies.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
The tongue helps people taste food, but structures on its surface also help them sense textures - something that's also very important when savoring a meal.
Precise Biometrics AB has successfully completed a rights issue with preferential rights, which has supplied the Company with SEK 54.0 million prior to issue costs. The rights issue was subscribed to 178% and is implemented to finance further expansion and increase market penetration in prioritized segments.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
With federal spending on Medicaid experiments soaring in recent years, a congressional watchdog said state and federal governments fail to adequately evaluate if the efforts improve care and save money.
The continuing efforts to make progress on the nation's health overhaul are reflected in today's headlines, which highlight both politics and policies.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 18.53 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 7.88 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 63.64 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 4.46 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.58 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 96.59 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.15 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 92.55 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 6.43 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 82.89 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0.83 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 39.17 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 13.8 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 8.52 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 90.86 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 60.27 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 68.45 | 82.93 |
News Archive
The tongue helps people taste food, but structures on its surface also help them sense textures - something that's also very important when savoring a meal.
Precise Biometrics AB has successfully completed a rights issue with preferential rights, which has supplied the Company with SEK 54.0 million prior to issue costs. The rights issue was subscribed to 178% and is implemented to finance further expansion and increase market penetration in prioritized segments.
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.
With federal spending on Medicaid experiments soaring in recent years, a congressional watchdog said state and federal governments fail to adequately evaluate if the efforts improve care and save money.
The continuing efforts to make progress on the nation's health overhaul are reflected in today's headlines, which highlight both politics and policies.
› Verified 2 days ago
Kenosha Estates Rehab And Care Center Location: 1703 60th St, Kenosha, Wisconsin 53140 Phone: (262) 658-4125 | |
Bay At Waters Edge Health And Rehabilitation (the) Location: 3415 N Sheridan Rd, Kenosha, Wisconsin 53140 Phone: (262) 657-6175 | |
Crossroads Care Center Of Kenosha Location: 8633 32nd Ave, Kenosha, Wisconsin 53142 Phone: (262) 694-8300 | |
Bay At Sheridan Health And Rehabilitation (the) Location: 8400 Sheridan Rd, Kenosha, Wisconsin 53143 Phone: (262) 658-4141 | |